Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma
Open Access
- 21 January 2005
- Vol. 103 (5) , 970-977
- https://doi.org/10.1002/cncr.20891
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLBlood, 2004
- Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell SupportNew England Journal of Medicine, 2004
- Effective Immunochemotherapy For Aggressive Non-Hodgkin’s LymphomaSeminars in Oncology, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell LymphomaNew England Journal of Medicine, 1997
- Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphomaAnnals of Oncology, 1997
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Treatment of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958